{"name":"Syntis Bio","slug":"syntis-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOMUF5R2loSHdrZ2tkMUhESXotRS0wWHk1TmVmeWdwOUM0N2xySjFIaUFORzBXcWw4eTNQX1NBSkh4eGl0bDQ2bHhoOXVzbFZSOF9XVlJ0ajZycWczTGhucnBaQlNOd0ljU04tMTRyTC11VzRDY25UM2dzajBOaS1EZHZFaGRlQmVFODREQ3g2STN3YWV0bzRPcGt5WWlYZTdIVnlJRWRQOGFnOEZsajRrM1IzRmhfT2RUMkk2OXhIaW8teGlMQjJpRERKcU1ySnJabEtmLVRndl9NaVR5M01OaDlMY1JfdlE3NjVFdk9xZVFHUEk?oc=5","date":"2026-03-03","type":"trial","source":"BioSpace","summary":"Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions - BioSpace","headline":"Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Addition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNVnNmUmtrY3lOZ0dfcmRIZnBhUThQQXAxbXhSX1MtZC13TUFrYkpnS0Q2YmRka0ZNQXItMTBmb3FRd2JuaFlaLUg0QV9pTmdqUFM5dUxDNGVRbzRRTEJuQk9md3JGWjNrNGZGT0htTkVBNXhBRjRXdUhDZW1DRWdQTmROLW80a2ZWS1R6QXJXd0xnXzBxcDR2NFRtQkZWN1p1dDB4SXhaNmFVS0lHTVNuallLVk5RdUEyY2NnNzdqaVB3bEF0U3BPT293?oc=5","date":"2025-07-02","type":"pipeline","source":"The Pharma Letter","summary":"Syntis Bio’s $38 million round to advance oral therapies for obesity and rare diseases - The Pharma Letter","headline":"Syntis Bio’s $38 million round to advance oral therapies for obesity and rare diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBVnZtSElHNTJDQWoweFpfU1FxekhDdnlxM3J0Y1JUamVyY1hjU3FvVHVfcWtwY0lUTGt3anI0b1hObVdRR05SUm9mdGtBU3diSTE0?oc=5","date":"2025-07-01","type":"pipeline","source":"FirstWord Pharma","summary":"Syntis Bio secures $33M to advance oral gastric bypass-mimicking asset - FirstWord Pharma","headline":"Syntis Bio secures $33M to advance oral gastric bypass-mimicking asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxON3RGcWd1U1BfVUtSOGNhc182OFk3Znh1eGdOa05yemphVGd4clJnNkdkLTBhYlFzRE05VkJvOVRhbjd6dUJZMDdFS1Q1aXpXU3RXWHlwcmNpdlgySVhzREljVG1CMzlTaFZvYlRIQ1lEdmFXOHFpTjdtY1V5bjFfb2taenRWYllTWmxIWmRDbGtJSmMtZzZYenlMTHRtNC1kRHIxaXdYZUpjMm1HUmNXLUlvblhnYUVxRFZYbDVFLUtFX1pfekFXU1NtRzNxbzVERVNXNEc0VE9Xdzh4bGFNaUpWWkJHTlY1dHQxczdB?oc=5","date":"2025-07-01","type":"pipeline","source":"Business Wire","summary":"Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases - Business Wire","headline":"Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPVWdRYTBDT2FxTDFHTnl6SkZlSlA0YVR2clI4RGZjd004MGNnN1BQTy1yd1NnRHFudkNLdGRUUWhac2dMekFndTRiclg5MkFTTUlEMlhoMGNqUGxiRmEyUEpfQWVJZloyWE5oTnJJSTl4SjFYSmhQLTBIdFdGajQ2eW9jTVJNSWhVdXRNODRWZ3RfVWZDd0lpNFpwa1FIUXJSR1JPTFZFYXNseE1fUTBENHlsMFc4Y1pwQWc?oc=5","date":"2025-07-01","type":"pipeline","source":"MedCity News","summary":"MIT Spinout Syntis Bio Secures $33M for a Novel Approach to Treating Obesity and More - MedCity News","headline":"MIT Spinout Syntis Bio Secures $33M for a Novel Approach to Treating Obesity and More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPUUNkTWlRS0pTbGdPcVo5YzUtN09neEp6OGhLUU84WkktaHpxd092MXZoaHlsWHR4R2NsRzgybklPbmVxeUJCMzNkTkoxX096QS1qeDkybnhRQkxsc1FqbGtZT2duZ1lkSlJvaDFuWVVTM3RLYTRKckRqaEZNaDR6dVNaUks1ZHF4bjJrWmlxNUhnWmFCRzFlVjNERkp0ME13T3V3YTJMbHhnc2ZoMnJwTDhFeHprQ2p1Rm9jczhxZnV3ZlpLN1RHU0h4R19WbDVGMVAtaGNLVFZPVHN1RjhUSVNPMzNvWjFiTXMwcXFkZzZ2VUdEVXFSN1c0NXJnTTdwcEF0NHRhN2xZTHpZOURaU0IxUlNkOEd2SmZQeEdPdWE0VUdxZU55ZDE3dTU1T1pUeFZITGE4V1ZrYVk?oc=5","date":"2025-04-10","type":"trial","source":"Business Wire","summary":"Syntis Bio Releases New Data Supporting Potential of SYNT-101 as a Once-Daily Oral Treatment for Obesity at European Congress on Obesity and Weight Management - Business Wire","headline":"Syntis Bio Releases New Data Supporting Potential of SYNT-101 as a Once-Daily Oral Treatment for Obesity at European Con","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNbFlkSXZRNUVHNGNsYWdDUkZPRGZKOU9qLTZCSzBvVmxYdVE1eGlkU0g5SHRtSm9OMHFrM0hYN1F1ZXZob0dFSXJONWJKb2o4YmdhT2ppQ1dxNmltazJMY0FnNjZHT21QaVdCQ005WkY5ekVEQ25GeGc3ZDJYOXNtT0d2QQ?oc=5","date":"2024-06-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"Syntis Bio to advance therapies for metabolic diseases - Pharmaceutical Technology","headline":"Syntis Bio to advance therapies for metabolic diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZEx3WTBlWnp0YUR0Mzc0RlNWdzhsQV9WcUN0clBkQmtaUmlROHpEUzdHbkRhcVFCRW5rX25hUy1obGEwSjg2MVBKTXJuMExpSmo4dWtJV1FYXzR6ZGNSN0ZSQV9KRWNiTGdUM1hVek56ejl5LTZ0anNjVTNrUGlEb1BqOVQ1NFZDRnRzM1FsaC1xLVRxbmR2bHVnNzdNM2JmTnladFdmWmZtZElkUzRHdk5yclExVGZfY01n?oc=5","date":"2024-06-11","type":"pipeline","source":"Fierce Biotech","summary":"Move over, GLP-1s. Syntis launches with clinical-stage obesity pill to mimic gastric bypass surgery - Fierce Biotech","headline":"Move over, GLP-1s. Syntis launches with clinical-stage obesity pill to mimic gastric bypass surgery","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}